Antisense modulation of CD36L 1 expression

• US 6,852,536 B2
• Filed: 12/18/2001
• Issued: 02/08/2005
• Est. Priority Date: 12/18/2001
• Status: Expired due to Fees

• Current Assignee: ISIS Pharmaceuticals Incorporated (Ionis Pharmaceuticals, Inc.)
• Original Assignee: ISIS Pharmaceuticals Incorporated (Ionis Pharmaceuticals, Inc.)
• Inventors: Dobie, Kenneth W.
• Primary Examiner(s): LeGuyader, John L.
• Assistant Examiner(s): SCHULTZ, JAMES
• Application Number:
  US10/024,396
• Publication Number:
  US 20030147864A1
• Time in Patent Office: 1,148 Days
• Field of Search: 514/44, 435/6, 435/375, 435/325, 536/24.5
• US Class Current: 435/375
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C12N 15/1138 against receptors or cell surface proteins
• CPC Class Codes: C12N 2310/315 Phosphorothioates
• CPC Class Codes: C12N 2310/321 2'-O-R Modification
• CPC Class Codes: C12N 2310/3341 5-Methylcytosine
• CPC Class Codes: C12N 2310/341 Gapmers, i.e. of the type ===---===
• CPC Class Codes: C12N 2310/346 having a combination of backbone and sugar modifications
• CPC Class Codes: C12N 2310/3525 MOE, methoxyethoxy
• CPC Class Codes: Y02P 20/582 Recycling of unreacted starting or intermediate materials

Abstract

Antisense compounds, compositions and methods are provided for modulating the expression of CD36L1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CD36L1. Methods of using these compounds for modulation of CD36L1 expression and for treatment of diseases associated with expression of CD36L1 are provided.

Claims

1. A compound 8 to 50 nucleobases in length targeted to nucleobases 336 through 363 of a coding region of a nucleic acid molecule encoding CD36L1 (SEQ ID NO:

3), wherein said compound is an antisense oligonucleotide with at least one modified internucleoside linkage and specifically hybridizes with said region and inhibits the expression of CD36L1.

2. The compound of claim 1 wherein the modified internucleoside linkage is a phosphorothioate linkage.

3. The compound of claim 1 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

4. The compound of claim 3 wherein the modified sugar moiety is a 2′

-o-methoxyethyl sugar moiety.

5. The compound of claim 1 wherein the antisense oiigonucleotide comprises at least one modified nucleobase.

6. The compound of claim 5 wherein the modified nucleobase is a 5-methylcytosine.

7. The compound of claim 1 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

8. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

9. The composition of claim 8 further comprising a colloidal dispersion system.

10. A method of inhibiting the expression of CD36L1 in cells or tissues comprising contacting said cells or tissues In vitro with the compound of claim 1 so that expression of CD36L1 is inhibited.